Original Research
Published on 31 May 2024
Risk of dyslipidemia and major adverse cardiac events with tofacitinib versus adalimumab in rheumatoid arthritis: a real-world cohort study from 7580 patients
in Pharmacoepidemiology
- 2,896 views
- 6 citations